Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD24m

    Last close

    AUD0.00

    ▲ 0.00 (50.00%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Ultimovacs (ULTI)

Last close As at 17/04/2024

NOK8.75

▲ −1.35 (−13.37%)

Market capitalisation

NOK348m

Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

View More

Healthcare | Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Healthcare | Flash note

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

Healthcare | edison tv

Ultimovacs – executive interview

Healthcare | Flash note

Ultimovacs — Another ODD boosts the off-the-shelf, universal UV1
Ultimovacs_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Carlos de Sousa

    CEO

  • Gustav Gaudernack

    CSO

  • Hans Vassgård Eid

    CFO

  • Jens Bjørheim

    CMO

  • Ton Berkien

    CBO

Balance Sheet

Forecast net debt (NOKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 18.2 (93.8) (93.3)
Relative 12.6 (94.2) (93.7)
52 week high/low NOK160.4/NOK6.3

Financials

Ultimovacs is focused on developing a cancer vaccine with universal potential. Lead asset UV1 activates the immune system to recognise cancer cells that express hTERT, which is present in c 85–90% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total, with readouts across 2023–25. While UV1 has demonstrated efficacy in mesothelioma (NIPU), recent results in melanoma (INITIUM) did not show the expected added benefit with UV1. The next readouts in head and neck cancer (FOCUS) are expected in Q324.

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 0.0 (181.0) (167.8) (489.9) N/A N/A
2023A 0.0 (213.0) (189.2) (550.1) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Flash note

Healthcare

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

edison tv

Healthcare

Ultimovacs – executive interview

Healthcare

Flash note

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Flash note

Healthcare

Ultimovacs — Another ODD boosts the off-the-shelf, universal UV1

Update

Healthcare

Ultimovacs — Universal approach with critical readouts in March
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — FDA Fast Track boosts confidence in UV1
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — INITIUM: March 2024 top-line timeline confirmed
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — TENDU results support TET platform expansion

edison tv

Healthcare

Ultimovacs – executive interview
Ultimovacs_resized

Update

Healthcare

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM
Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Line of sight on INITIUM top-line readout
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free